A

Advaxis Inc
OTC:ADXS

Watchlist Manager
Advaxis Inc
OTC:ADXS
Watchlist
Price: 0.03 USD Market Closed
Market Cap: 1.3m USD

ADXS's latest stock split occurred on Jun 6, 2022

The company executed a 1-for-80 stock split, meaning that for every 80 shares held, investors received 1 new share.

Before the split, ADXS traded at 4.96 per share. Afterward, the share price was about 4.96.

The adjusted shares began trading on Jun 6, 2022. This was ADXS's 3rd stock split, following the previous one in Mar 29, 2019.

Last Splits:
Jun 6, 2022
1-for-80
Mar 29, 2019
1-for-15
Jul 15, 2013
1-for-125
Pre-Split Price
4.96 4.96
Post-Split Price
4.96
Before
After
Last Splits:
Jun 6, 2022
1-for-80
Mar 29, 2019
1-for-15
Jul 15, 2013
1-for-125

Advaxis Inc
Stock Splits History

ADXS Stock Splits Timeline
Jun 6, 2022
Jun 6, 2022
Split 1-for-80
/0.0125
Pre-Split Price
4.96 4.96
Post-Split Price
4.96
Before
After
Mar 29, 2019
Mar 29, 2019
Split 1-for-15
/0.066666666666667
Pre-Split Price
461.9977 461.9977
Post-Split Price
472.8
Before
After
Jul 15, 2013
Jul 15, 2013
Split 1-for-125
/0.008
Pre-Split Price
5 849.9707 5 849.9707
Post-Split Price
7 043.9648
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
May 13, 2025
L
Lithos Energy Ltd
OTC:LITSF
1-for-10
/10
0.13 0.13 USD 0.0858 0.0858 USD
May 13, 2025
N
New Zealand Coastal Seafoods Ltd
OTC:NZSCF
1-for-10
/10
0.0003 0.003 USD 0.003 0.003 USD
May 13, 2025
Sienna Resources Inc
OTC:SNNAF
1-for-10
/10
0.155 0.155 USD N/A
May 13, 2025
S
Smec Co Ltd
KOSDAQ:099440
3958-for-3333
x1.1875187518752
2353.6471 2353.6471 KRW 2390 2390 KRW
May 12, 2025
C
Comprehensive Healthcare Systems Inc
XTSX:CHS
1-for-20
/20
0.01 0.2 CAD 0.2 0.2 CAD
Load More

Advaxis Inc
Glance View

Market Cap
1.3m USD
Industry
Biotechnology

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. The company is headquartered in Monmouth Junction, New Jersey and currently employs 15 full-time employees. The company went IPO on 2005-07-28. The Company’s products are based on a platform technology, which utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. The company is focused on single antigen and multiple antigen delivery products. The firm's pipeline of product candidates includes ADXS-503, which develops for treatment of non-small cell lung cancer; ADXS-504, which develops for the treatment of early-stage prostate cancer; and ADXS-PSA, which develops for the treatment of metastatic prostate cancer. Its ADXS-503 and ADXS-503 are in Phase I clinical trial. ADXS-PSA is in Phase II clinical trial. The company has completed and closed out clinical studies of Lm Technology immunotherapies in three program areas, HPV associated cancers, Personalized neoantigen-directed therapies and PSA directed therapy.

ADXS Intrinsic Value
0.0005 USD
Overvaluation 98%
Intrinsic Value
Price
A
Back to Top